MOUNTAINSIDE, N.J., April 4, 2016 /PRNewswire/ -- Androvia LifeSciences, a biotechnology company engineering solutions for the advancement of male fertility, today announced that data related to the company's proprietary technology, the Cap-Score™ Sperm Function Test, will be presented at the American Urological Association (AUA) 2016 Annual Meeting, to be held May 6 – 10 in San Diego, California.
"While female factors have been the driving force in directing the best fertility solutions for a couple, the Cap-Score Sperm Function Test focuses on the male factor in the decision making process," said Michael V. Novinski, chief executive officer, Androvia LifeSciences.
This new information was presented at the 41st Annual Conference of the American Society of Andrology (ASA), April 2 – 5, 2016, New Orleans, Louisiana.
The study being presented at the AUA annual meeting this year is:
Impacts of Common Semen Handling Methods on Sperm Function
An abstract summarizing these data was published today on the AUA website and is available to conference registrants and AUA members at: www.aua2016.org.
About Cap-Score Sperm Function Test
A laboratory developed test being designed to assess and measure the fertilizing ability of sperm, to help couples and reproductive health care professionals make informed decisions about the fertility solution that is best suited for that couple. The Cap-Score Sperm Function Test provides an analysis of the sperm on a molecular level, and is the only assay that evaluates capacitation, the process by which sperm acquire the ability to fertilize an egg. The test is being designed to complement the traditional semen analysis which determines sperm count, motility and appearance.
About Androvia LifeSciences
Androvia LifeSciences is a biotechnology company focused on engineering scientific technology for the advancement of male fertility, and empowering couples with the information to help determine personalized fertility solutions.
SOURCE Androvia LifeSciences